ERBB2 and ovarian cancer: In contrast, Tras and Per IgE mediated ADCC against HER2-expressing cancer cells in an antigen-density dependent manner, an observation in accordance with previous reports with the anti-FRα MOv18 IgE antibody targeting ovarian cancer.16